Gray Lady Gives Up the Ghost

  • by: |
  • 04/21/2008

Over a year ago the Wall Street Journal published a piece “exposing” that some medical journal articles are – gasp – drafted by professional medical writers and then edited (often heavily so) by the bylined authors before they are published!

 

The New York Times must have missed it, because on Saturday the New York Times ran a very similar article.  All the news that’s fit to print? 

 

Here’s how Stephanie Saul began her article, “The pharmaceutical industry glimpsed its own ghost this week, and the apparition could not have arrived at a worse time for drug makers.”

 

Cute.  Here’s a link to the complete article:

 

www.nytimes.com/2008/04/19/business/19ghost.html


Ms. Saul’s represents only the latest example of the media positioning ANYTHING paid for, promoted, supported, encouraged, approved, or assisted by Big Pharma has BAD. And not just BAD but REALLY BAD. SO BAD, in fact, that it deserves the full evil empire treatment. The “issue” the article is pegged to is the FDA’s brave stance on the free and fair dissemination of scientific data (aka:  journal articles) by pharmaceutical companies to physicians and other audiences. According to Ms. Saul, this controversy (made new again by a report that Merck used ghost writers for journal articles relating to Vioxx) “
raised new questions about the validity of many published research studies, even in peer-reviewed publications.”   I thought passive voice was a no-no in journalism?

 

The real question on the table is whether it’s right and appropriate for pharmaceutical companies to be involved in the drafting of medical journal articles that are based on their own studies of their own products.  Hullo?  Okay, let’s try this – how about, is it right and appropriate for pharmaceutical companies to blur the line between marketing and science?  That’s a better question, but it presupposes that all marketing is bad and all science is good. 

 

Let’s pursue that proposition.  Who would think marketing and science make poor bedfellows?  Well, cui bono? Surprise! The people at the front of the anti-marketing, pro-science queue are the editors of our medical journals.  After all, if these self-appointed Sultans of Science cease to be the singular gatekeepers of new scientific information then, quite logically, the world will come to an end.  The canard that ghostwritten articles in any way denigrate the nature of the material is such a transparent and disingenuous attempt on the part of medical journal editors to discredit the pharmaceutical industry that it is (or should be) embarrassing.  It brings into real question the better (Marcia) angels of their nature.

 

Other folks with an agenda here (and who are portrayed in the New York Times story as “advocates”) are those who have a vested interest in not having more expensive drugs available for patient care – aka payers.  And, of course, there’s the mandatory quote from Sid Wolfe.

 

Next time you read an op-ed in your favorite newspaper by a well-known personage consider if a ghostwriter was employed.  Answer:  Probably.  Next time you hear your favorite politician give an address ask yourself if the speaker wrote the speech.  Answer:  Probably not.  And then ask yourself this – does it make a difference?  If the article or the address truly represents the beliefs of the “byline,” then it’s like that TV commercial, “We don’t make a lot of the things you use.  We make a lot of the things you use better.”

 

Me, personally, I’d rather read articles that are well written. I also believe that if the incursion of professional writing assistance makes the articles better, then that’s a good thing because it tends to make dense data more easily understandable.

 

Isn’t that the point? Or is it just me?


CMPI

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
AHRP
Better Health
BigGovHealth
Biotech Blog
BrandweekNRX
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
CNEhealth.org
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
eDrugSearch
Envisioning 2.0
EyeOnFDA
FDA Law Blog
Fierce Pharma
fightingdiseases.org
Fresh Air Fund
Furious Seasons
Gooznews
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
IgniteBlog
In the Pipeline
In Vivo
Instapundit
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
KevinMD
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
Medrants
More than Medicine
National Review
Neuroethics & Law
Newsbusters
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
PAL
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmablogger
Pharmacology Corner
Pharmagossip
Pharmamotion
Pharmalot
Pharmaceutical Business Review
Piper Report
Polipundit
Powerline
Prescription for a Cure
Public Plan Facts
Quackwatch
Real Clear Politics
Remedyhealthcare
Shark Report
Shearlings Got Plowed
StateHouseCall.org
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
TortsProf
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog